Search Results

The Reten-World survey of the management of acute urinary retention: preliminary results

Authors: Emberton, Mark; Fitzpatrick, John M.

Source: BJU International, Volume 101, Supplement 3, March 2008 , pp. 27-32(6)

Publisher: Blackwell Publishing

Ocular Pharmacokinetic/Pharmacodynamic Modeling for Bunazosin After Instillation into Rabbits

Authors: Sakanaka K.; Kawazu K.; Tomonari M.; Kitahara T.; Nakashima M.; Kawakami S.; Nishida K.; Nakamura J.; Sasaki H.

Source: Pharmaceutical Research, Volume 21, Number 5, May 2004 , pp. 770-776(7)

Publisher: Springer

The Management of Prostatic Obstruction: How to Determine the Best Options?

Authors: Roehrborn C.G.; McNicholas T.

Source: European Urology Supplements, Volume 2, Number 8, November 2003 , pp. 13-19(7)

Publisher: Elsevier

Novel Therapeutic Strategies for Managing BPH Progression

Authors: Djavan B.; Barkin J.

Source: European Urology Supplements, Volume 2, Number 8, November 2003 , pp. 20-26(7)

Publisher: Elsevier

Voiding impairment after prostate biopsy: does tamsulosin treatment before biopsy decrease this morbidity?

Authors: Bozlu M.; Ulusoy E.; Doruk E.; Cayan S.; Canpolat B.; Schellhammer P.F.; Akbay E.

Source: Urology, Volume 62, Number 6, December 2003 , pp. 1050-1053(4)

Publisher: Elsevier

Urodynamic effects of 1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder

Authors: KAKIZAKI H.; AMEDA K.; KOBAYASHI S.; TANAKA H.; SHIBATA T.; KOYANAGI T.

Source: International Journal of Urology, Volume 10, Number 11, November 2003 , pp. 576-581(6)

Publisher: Blackwell Publishing

Safety and Tolerability of the Dual 5-Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic Hyperplasia

Authors: Andriole G.L.; Kirby R.

Source: European Urology, Volume 44, Number 1, July 2003 , pp. 82-88(7)

Publisher: Elsevier

Long-Term Safety and Efficacy of a Once-Daily Formulation of Alfuzosin 10 mg in Patients with Symptomatic Benign Prostatic Hyperplasia: Open-Label Extension Study

Authors: van Kerrebroeck P.; Jardin A.; van Cangh P.; Laval K.U.; The ALFORTI Study Group

Source: European Urology, Volume 41, Number 1, January 2002 , pp. 54-61(8)

Publisher: Elsevier

Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy

Authors: Kloner R.A.; Brown M.; Prisant L.M.; Collins M.; Sildenafil Study Group

Source: American Journal of Hypertension, Volume 14, Number 1, January 2001 , pp. 70-73(4)

Publisher: Elsevier

Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients

Authors: Hirano T.; Yoshino G.; Kashiwazaki K.; Adachi M.

Source: American Journal of Hypertension, Volume 14, Number 9, September 2001 , pp. 908-913(6)

Publisher: Elsevier

Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial¹

Authors: Roehrborn C.G.; for the ALFUS STUDY GROUP

Source: Urology, Volume 58, Number 6, December 2001 , pp. 953-959(7)

Publisher: Elsevier

Emotional stress activates MAP kinase in the rat heart

Authors: Ueyama T.; Aki T.; Senba E.; Hatanaka K.; Yoshida K.

Source: Life Sciences, Volume 69, Number 16, 7 September 2001 , pp. 1927-1934(8)

Publisher: Elsevier

Interaction of alcohol and an ₁-blocker on ambulatory blood pressure in patients with essential hypertension

Authors: Kawano Y.; Abe H.; Kojima S.; Takishita S.; Omae T.

Source: American Journal of Hypertension, Volume 13, Number 3, March 2000 , pp. 307-312(6)

Publisher: Elsevier

Modulation of tumor necrosis factor- production with anti-hypertensive drugs

Authors: Fukuzawa M.; Satoh J.; Ohta S.; Takahashi K.; Miyaguchi S.; Qiang X.; Sakata Y.; Nakazawa T.; Takizawa Y.; Toyota T.

Source: Immunopharmacology, Volume 48, Number 1, June 2000 , pp. 65-74(10)

Publisher: Elsevier

Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications

Authors: Lowe F.C.; Olson P.J.; Padley R.J.

Source: Urology, Volume 54, Number 1, July 1999 , pp. 81-85(5)

Publisher: Elsevier

Effects of doxazosin in patients with mild, intermediate, and severe benign prostatic hyperplasia

Authors: Mobley D.F.; Dias N.; Levenstein M.

Source: Clinical Therapeutics, Volume 20, Number 1, January 1998 , pp. 101-109(9)

Publisher: Elsevier

Alpha-Blockade Therapy for Benign Prostatic Hyperplasia: from a Nonselective to a More Selective Alpha_1A-Adrenergic Antagonist - pharmacodynamic effect

Authors: Beduschi M.C.; Beduschi R.; Oesterling J.E.

Source: Urology, Volume 51, Number 6, June 1998 , pp. 861-872(12)

Publisher: Elsevier

Pharmacological, electrophysiological and toxicity studies of Limacia scanden Lour. (Menispermaceae)

Authors: Hwi K.K.; Lay W.B.

Source: Journal of Ethnopharmacology, Volume 62, Number 2, September 1998 , pp. 137-148(12)

Publisher: Elsevier

Postischemic Left Ventricular Dysfunction Is Abolished by Alpha-Adrenergic Blocking Agents

Authors: Gregorini L.; Marco J.; Palombo C.; Kozakova M.; Anguissola G.B.; Cassagneau B.; Bernies M.; Distante A.; Marco I.; Fajadet J.; Zanchetti A.

Source: Journal of the American College of Cardiology, Volume 31, Number 5, April 1998 , pp. 992-1001(10)

Publisher: Elsevier

Effect of Bunazosin and Atenolol on Glucose Metabolism in Obese, Nondiabetic Patients with Primary Hypertension

Authors: Bönner G.; Schmieder R.; Chrosch R.; Weidinger G.

Source: Cardiovascular Drugs and Therapy, Volume 11, Number 1, March 1997 , pp. 21-26(6)

Publisher: Springer